An Inverse Correlation of Serum Fibroblast Growth Factor 19 with Abdominal Pain and Inflammatory Markers in Patients with Ulcerative Colitis

Background and Aims. Bile acids (BA) play an important role in the modulation of numerous gut functions. Fibroblast growth factor 19 (FGF19) is the ileal hormone regulating BA homeostasis. The aim of the study was to evaluate serum FGF19 level and its correlation with clinical and endoscopic disease...

Full description

Saved in:
Bibliographic Details
Main Authors: Magdalena Panek-Jeziorna, Agata Mulak
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2020/2389312
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832549953770094592
author Magdalena Panek-Jeziorna
Agata Mulak
author_facet Magdalena Panek-Jeziorna
Agata Mulak
author_sort Magdalena Panek-Jeziorna
collection DOAJ
description Background and Aims. Bile acids (BA) play an important role in the modulation of numerous gut functions. Fibroblast growth factor 19 (FGF19) is the ileal hormone regulating BA homeostasis. The aim of the study was to evaluate serum FGF19 level and its correlation with clinical and endoscopic disease activity indices along with inflammatory biomarkers including serum CRP and fecal calprotectin levels in patients with ulcerative colitis (UC). Methods. Fasting serum FGF19 level was measured using ELISA test in 16 patients with active UC (7 F, 9 M), 15 patients with nonactive UC (8 F, 7 M), and 19 healthy controls (11 F, 8 M). The disease activity was assessed based on the clinical and endoscopic evaluations as well as serum CRP and fecal calprotectin level measurement. Results. The median serum FGF19 level was higher in patients with nonactive UC (175.3 pg/ml (108.7-342.3)) than in patients with active UC (114.3 pg/ml (68.9-155.3), p=0.093). The median FGF19 level in healthy controls amounted to 151.6 pg/ml (90.6-224.2), and there were no statistically significant differences between the patients with active and nonactive UC compared to the healthy controls. An inverse correlation was observed between FGF19 level and abdominal pain intensity (R=–0.48, p=0.007) as well as fecal calprotectin (R=–0.38, p=0.036) and CRP levels (R=–0.36, p=0.045). The serum FGF19 level was not correlated neither with clinical nor endoscopic disease activity indices. Conclusions. The inverse correlations between FGF19 level and abdominal pain as well as inflammatory markers in UC may imply its potential analgesic and anti-inflammatory effects.
format Article
id doaj-art-9e3f567a9f9549e38f8989e4ce75f92e
institution Kabale University
issn 1687-6121
1687-630X
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Gastroenterology Research and Practice
spelling doaj-art-9e3f567a9f9549e38f8989e4ce75f92e2025-02-03T06:08:07ZengWileyGastroenterology Research and Practice1687-61211687-630X2020-01-01202010.1155/2020/23893122389312An Inverse Correlation of Serum Fibroblast Growth Factor 19 with Abdominal Pain and Inflammatory Markers in Patients with Ulcerative ColitisMagdalena Panek-Jeziorna0Agata Mulak1Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, PolandDepartment of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, PolandBackground and Aims. Bile acids (BA) play an important role in the modulation of numerous gut functions. Fibroblast growth factor 19 (FGF19) is the ileal hormone regulating BA homeostasis. The aim of the study was to evaluate serum FGF19 level and its correlation with clinical and endoscopic disease activity indices along with inflammatory biomarkers including serum CRP and fecal calprotectin levels in patients with ulcerative colitis (UC). Methods. Fasting serum FGF19 level was measured using ELISA test in 16 patients with active UC (7 F, 9 M), 15 patients with nonactive UC (8 F, 7 M), and 19 healthy controls (11 F, 8 M). The disease activity was assessed based on the clinical and endoscopic evaluations as well as serum CRP and fecal calprotectin level measurement. Results. The median serum FGF19 level was higher in patients with nonactive UC (175.3 pg/ml (108.7-342.3)) than in patients with active UC (114.3 pg/ml (68.9-155.3), p=0.093). The median FGF19 level in healthy controls amounted to 151.6 pg/ml (90.6-224.2), and there were no statistically significant differences between the patients with active and nonactive UC compared to the healthy controls. An inverse correlation was observed between FGF19 level and abdominal pain intensity (R=–0.48, p=0.007) as well as fecal calprotectin (R=–0.38, p=0.036) and CRP levels (R=–0.36, p=0.045). The serum FGF19 level was not correlated neither with clinical nor endoscopic disease activity indices. Conclusions. The inverse correlations between FGF19 level and abdominal pain as well as inflammatory markers in UC may imply its potential analgesic and anti-inflammatory effects.http://dx.doi.org/10.1155/2020/2389312
spellingShingle Magdalena Panek-Jeziorna
Agata Mulak
An Inverse Correlation of Serum Fibroblast Growth Factor 19 with Abdominal Pain and Inflammatory Markers in Patients with Ulcerative Colitis
Gastroenterology Research and Practice
title An Inverse Correlation of Serum Fibroblast Growth Factor 19 with Abdominal Pain and Inflammatory Markers in Patients with Ulcerative Colitis
title_full An Inverse Correlation of Serum Fibroblast Growth Factor 19 with Abdominal Pain and Inflammatory Markers in Patients with Ulcerative Colitis
title_fullStr An Inverse Correlation of Serum Fibroblast Growth Factor 19 with Abdominal Pain and Inflammatory Markers in Patients with Ulcerative Colitis
title_full_unstemmed An Inverse Correlation of Serum Fibroblast Growth Factor 19 with Abdominal Pain and Inflammatory Markers in Patients with Ulcerative Colitis
title_short An Inverse Correlation of Serum Fibroblast Growth Factor 19 with Abdominal Pain and Inflammatory Markers in Patients with Ulcerative Colitis
title_sort inverse correlation of serum fibroblast growth factor 19 with abdominal pain and inflammatory markers in patients with ulcerative colitis
url http://dx.doi.org/10.1155/2020/2389312
work_keys_str_mv AT magdalenapanekjeziorna aninversecorrelationofserumfibroblastgrowthfactor19withabdominalpainandinflammatorymarkersinpatientswithulcerativecolitis
AT agatamulak aninversecorrelationofserumfibroblastgrowthfactor19withabdominalpainandinflammatorymarkersinpatientswithulcerativecolitis
AT magdalenapanekjeziorna inversecorrelationofserumfibroblastgrowthfactor19withabdominalpainandinflammatorymarkersinpatientswithulcerativecolitis
AT agatamulak inversecorrelationofserumfibroblastgrowthfactor19withabdominalpainandinflammatorymarkersinpatientswithulcerativecolitis